Wong, Harvey - University of British Columbia - Faculty of Pharmaceutical Sciences

个人简介

Dr. Harvey Wong is an Associate Professor of Pharmacokinetics in the Faculty of Pharmaceutical Sciences. He obtained his B.Sc. in pharmacy, and Ph.D. in pharmacokinetics and biopharmaceutics at UBC. Following graduation, Dr. Wong was employed in pharmaceutical industry at the DuPont Pharmaceuticals Company, Bristol-Myers Squibb, and most recently at Genentech in the areas of oncology, neuroscience, and immunology. At Genentech, he served as a research project team leader, a non-clinical development team leader, and gained extensive experience in regulatory filings. Most notably, Dr. Wong was part of the team involved in the development of vismodegib (Erivedge®), the first in class hedgehog pathway inhibitor, which was awarded the "Drug Discovery of the Year" award in 2012 by the British Pharmacological Society. Dr. Wong's expertise is in drug discovery and development strategies with a specialization in ADME, pharmacokinetics, and modeling and simulation (translational PK/PD analysis, systems pharmacology, and physiologically based pharmacokinetic modeling). He currently chairs the PK/PD Discussion Group for the IQ Consortium and serves on the Editorial Board of Biopharmaceutics and Drug Disposition.

研究领域

Dr. Harvey Wong's research interests include applications of translational modeling and simulation techniques to optimize drug dose and regimen for new therapeutics, and to better understand emergence of cancer tumor drug resistance.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Physiologically-based pharmacokinetic models of small molecules and therapeutic antibodies: mini-review on fundamental concepts and applications, Ferl, Gregory Z., Theil Frank-Peter, and Wong Harvey , Biopharmaceutics & Drug Disposition, Jan-10-2015, p.n/a - n/a, (2015) Mechanistic Pharmacokinetic-Pharmacodynamic Modeling of BACE1 Inhibition in Monkeys: Development of a Predictive Model for Amyloid Precursor Protein Processing, Liu, X., Wong H., Scearce-Levie K., Watts R. J., Coraggio M., Shin Y. G., Peng K., Wildsmith K. R., Atwal J. K., Mango J., et al. , Drug Metabolism and Disposition, Jan-07-2013, Volume 41, Issue 7, p.1319 - 1328, (2013) Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic-Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor, Wong, H., Vernillet L., Peterson A., Ware J. A., Lee L., Martini J.-F., Yu P., Li C., Rosario G. D., Choo E. F., et al. , Clinical Cancer Research, Jan-06-2012, Volume 18, Issue 11, p.3090 - 3099, (2012) Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response, Wong, H., Choo E. F., Alicke B., Ding X., La H., McNamara E., Theil F.-P., Tibbitts J., Friedman L. S., Hop C. E. C. A., et al. , Clinical Cancer Research, Mar-07-2013, Volume 18, Issue 14, p.3846 - 3855, (2012) Pharmacokinetic-Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation, Wong, H., Alicke B., West K. A., Pacheco P., La H., Januario T., Yauch R. L., de Sauvage F. J., and Gould S. E. , Clinical Cancer Research, Mar-07-2012, Volume 17, Issue 14, p.4682 - 4692, (2011)